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ABSTRACT 
Following the success of silicate-based glasses as bioactive materials, silicates are believed to 
play important roles in promoting bone formation and have therefore been considered to provide 
a hydroxyapatite surface layer capable of binding to bone as well as potentially being a pro-
osteoinductive factor. Natural silicate minerals and silicate-substituted hydroxyapatites are also 
being actively investigated as orthopaedic bone and dental biomaterials for application in tissue 
engineering. However, the mechanisms for the proposed roles of silicate in these materials have 
not been fully understood and are controversial. Here, we review the potential roles of silicate for 
bone tissue engineering applications and recent breakthroughs in identifying the cellular-level 
molecular mechanisms for the osteoinductivity of silica. The goal of this article is to inspire new 
ideas for the rational design of third-generation cell-and gene-affecting biomaterials. 
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1. Introduction  
The importance of replacing or regenerating bone becomes clear in the cases of diseases such 
as osteogenesis imperfecta, Paget’s disease, and osteoporosis in which normal bone development 
or turnover are impaired, and in situations where bone is surgically removed because of severe 
trauma or infection [1]. Replacement of damaged, diseased or aged bone tissue has become 
routine as a result of the development of reliable and affordable biomaterials and perfection of 
surgical procedures for implantation of prostheses and subsequent rehabilitation of patients [2]. 
The treatments involving bone repair and replacement have improved and saved countless lives 
[3]. Since the development of the concept of tissue engineering, the emphasis on developing 
novel materials has shifted from bone tissue replacement to tissue regeneration [4]. 
Bone tissue engineering requires bioactive and osteoinductive materials that mimic some of 
the features of native bone tissue, present a physiochemical biomimetic environment, and 
actively promote desirable responses. To address these requirements, a variety of materials have 
been investigated including metals, glasses, ceramics, polymers and composites of these 
materials. Ceramics and glasses of specific compositions are considered to be bioactive as they 
can bond to bone and enhance bone tissue formation. These formulations of ceramics and glasses 
include not only the chemical constituents (calcium and phosphate) of natural bone mineral, but 
also silicate, which normally occurs at trace levels in bone [5, 6]. The choice of calcium and 
phosphate is not surprising as these ions constitute the mineral phase of bone [7], but it is hard to 
understand why and how silicate works. In this paper, we first provide a brief history of how 
silicate entered the field of orthopaedic biomaterials and tissue engineering materials. Different 
types of silicate-based biomaterials, including glasses and ceramics are reviewed, and the roles 
of silicate in these materials are highlighted along with recent contradictory reports in the 
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literatures. Finally several mechanisms that can potentially explain the biological roles of silicate 
are presented. 
2. Why silicate? 
Silicon (Si) is the eighth-most common element in the universe by mass, and the second-most 
abundant element in the earth’s crust (about 28% as various forms of silica or silicate) after 
oxygen [8]. Si is also found in all living organisms [5]. It has been proposed to play an important 
biological role in humans [5] and play an essential role in organisms such as diatoms that use 
SiO2 to produce their exoskeleton [9-12]. Si is present at a level of ~ 1 ppm in the serum, 2-10 
ppm in the liver, kidney, lungs and muscle, 100 ppm in bone and 200-600 ppm in cartilage and 
other connective tissue [13]. The earliest study of Si in bone dates back to the early 1970s. Using 
electron probe microanalysis, Carlisle observed that Si levels were highest (0.5 wt%) during the 
earliest stages of bone calcification when Ca/P ratios are low (Ca/P = 0.7) compared to the ratio 
(Ca/P = 1.67) in stoichiometric hydroxyapatite (HAP). Subsequently, Si levels were observed to 
fall below the detection limit as mineralization proceeded, and the Ca/P of bone increased 
towards that of ideal stoichiometric HAP (Ca10(PO4)6(OH)4) [14]. Thus, Si was shown to be 
localized at active calcification sites in the bones of young mice and rats. Additionally, Si-
deprivation experiments were performed in chicks [15] that were fed a diet consisting of casein 
and corn with a very low silicate content of 2 mg/g or fed the same diet supplemented with 100 
mg/g Si as sodium metasilicate. After 4 weeks, the average mass of Si-deprived chicks was 76 g, 
compared to the mass of 116 g for Si-supplemented chicks. Skull deformities (shorter skull and 
distortion around the eye sockets), shorter, thinner, and more flexible limb bones that were easily 
fractured as well as the absence of a wattle and comb were reported in the Si-deprived chicks 
[15]. Lower levels of collagen were also observed in the cartilage of Si-deficient chicks, but no 
Page 4 of 48
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
5 
 
difference in the level of non-collagenous proteins [16, 17]. Carlisle et al. demonstrated that Si 
was required for normal bone growth and development in higher animals (Fig. 1). In a similar 
study by Schwartz and Milne in rats, hair loss, seborrhoea, loss of muscle tone, disturbances in 
enamel development and impairment of incisor pigmentation were observed [18]. Taken together, 
these findings indicated potentially important roles of Si in the formation of bone and other 
connective tissues such as cartilage. Therefore, Si may be categorized as an essential trace 
element for metabolic processes associated with the development of bone and connective tissues, 
and the localization of Si is at the growing front of bone. 
Figure 1 
A recent study using dietary Si supplementation in ovariectomized mice showed that trabecular 
bone volume decreased by 48% in untreated animals compared to the groups which received 
either aqueous silicate or estradiol, an inhibitor of the resorption activity of osteoclasts [19]. Si 
deficiency in ovariectomized animals also lead to a decrease in the concentration of plasma 
osteopontin, an important factor in bone remodeling, especially in anchoring osteoclasts to the 
mineral matrix of bone [20]. Furthermore, differences in dietary Si intake were positively and 
significantly linked to bone mineral density (BMD) at all hip measurement sites in men and 
premenopausal women with BMD differences as large as 10% between the highest (> 40 mg 
Si/day) and lowest levels (< 14 mg Si/day) of Si intake [21]. Si played a role in the remodeling 
process of bone [19, 20] and may inhibit the physiological resorption process. 
In summary, Si appears to be required for the formation of bone and is associated with both the 
inorganic and the organic phases of bone. Hence, Si has been incorporated in the design of many 
orthopaedic implant materials. 
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3. Silicate in biomaterials 
3.1 Silicate in bioactive glasses 
The positive effect of Si on bone metabolism has raised the interest of research groups working 
on bone graft substitutes. In the early 1970s, Hench and his co-workers discovered that specific 
melt-derived four-component glasses composed of SiO2, CaO, Na2O and P2O5 could bond with 
bone after implantation in vivo without the need for a cement at the time of surgery [22-26]. 
When immersed in biological fluids, a layer of HAP or hydroxyl carbonated apatite (HCA) 
similar to the mineral phase of bone, was deposited on the glass surface. Therefore, these specific 
glasses were termed bioactive because they promoted a positive response from the tissue; more 
specifically, they are osteoconductive. The bonding rate to existing bone tissue was specific to 
the bioactive glass composition [27]. In particular, the most rapid rates of bonding were obtained 
for bioactive glasses with SiO2 contents of 45-52 wt%, which bonded to both soft and hard 
connective tissue within 5-10 days. Bioactive glasses containing 55-60 wt% SiO2 required a 
longer time to bond with bone but did not bond to soft tissue [28]. Glass compositions with more 
than 60 wt% SiO2 were biologically inert because they bonded neither to bone nor to soft tissues 
and, eventually, elicited the formation of a non-adherent fibrous interfacial capsule (Fig. 2) [29].  
Figure 2 
The index of bioactivity (Ib) is defined as the inverse of the time required for more than 50% of 
the bone-material interface to be bonded (Ib = 100/t0.5bb). In the SiO2-CaO-Na2O-P2O5 system, 
glass compositions from 40-52 wt% SiO2 have Ib values varying from 12.5 to 10. The most 
bioactive composition (45 wt% SiO2, 24.5 wt% CaO, 24.5 wt% Na2O and 6 wt% P2O5) was 
named “Bioglass®”. This was the first bioactive material, discovered in 1969 [30], and has found 
Page 6 of 48
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
7 
 
many applications in the orthopaedic and dental fields. Even today it is considered to be one of 
the most successful materials to regenerate bone [22]. 
Clark and Hench [31] first proposed a detailed sequence of reactions occurring in vitro at the 
surface of silicate-based bioactive glasses immersed in simulated body fluid (SBF): (i) rapid 
exchange of Na+ and Ca2+ in the glass with H+ in solution; (ii) release of soluble silicate as 
Si(OH)4 by hydrolysis of Si-O-Si bridges in the glass with the formation of surface silanol 
groups; (iii) condensation and repolymerization of surface silanols with soluble silicate to form 
an amorphous SiO2-rich surface layer; (iv) migration of Ca
2+ and PO4
3- to the surface through the 
silica-rich layer and formation of a calcium phosphate (CaP) rich layer on the glass surface; (v) 
incorporation of OH- and CO3
2- from the solution and subsequent crystallization of the Ca-P 
layer to form HCA (Fig. 3, [32]). After these physical-chemical reactions occur, biological 
moieties can interact with the glass surface. Collagen molecules are incorporated in the HCA 
layer, and then cells begin to respond, leading ultimately to bone growth. The bonding 
mechanism was proven via microscopy, which showed the interface between bone and bioactive 
glass in a 4-week rat tibial implant [31]. 
Figure 3 
The behavior of glasses of different compositional ranges was explained on the basis of the rate 
of dissolution compared to the rates of cell responses such as attachment, proliferation and 
differentiation. Thus, it was noted that Fig. 2 represents kinetic boundaries and is not a phase 
diagram. Only glasses that dissolve rapidly bond to soft tissue (Region E in Fig. 2) and glasses 
with more than 52 wt % SiO2 bond to bone but not to soft tissue. For glasses that dissolve too 
slowly, the concentrations of the released ionic products are too low to promote cell proliferation 
and differentiation.  
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The authors also defined two classes of bioactivity based on the glass compositional range and 
biological response elicited. Class A bioactive glasses dissolve rapidly and induce both 
extracellular and intracellular responses (i.e., are both osteoconductive and osteoinductive), 
whereas class B bioactive materials dissolve more slowly and elicit only extracellular responses 
(i.e., are only osteoconductive). Note that these “A” and “B” classes are not to be confused with 
regions A and B in Fig. 2. 
3.2 Silicate in calcium phosphate bioceramics 
Synthetic stoichiometric HAP has been utilized extensively as a skeletal replacement material. 
However, synthetic HAP exhibits limited ability to form an osteoconductive bond with existing 
bone in vivo in a rabbit model; the response may take several days [33] when compared to 
bioactive glasses in which the reactions occur in just a few minutes [34]. Moreover, 
stoichiometric HAP is relatively insoluble and does not degrade significantly, which can be a 
limiting factor in creating space for new bone tissue formation [35]. Additionally, the mineral 
found in bone is not a stoichiometric compound, but exhibits variable deficiencies in Ca, P and 
OH [36]. Various substitutions exist in bone mineral, in particularly, carbonate anion is found at 
up to 8 wt%, as well as elements such as Na, Mg, K, Sr, Zn, Ba, Cu, Al, Fe, F, Cl, and Si that can 
occur at trace (< 1 wt%) levels [37]. These substitutions in the apatite structure play important 
roles in the biological activity of bone mineral by influencing the solubility, surface chemistry, 
crystal size, and morphology of the bone mineral. Inspired by the positive effects of silicate on 
bone metabolism, some research groups have made efforts to develop silicate-containing CaP as 
bone graft substitutes, such as silicate-substituted HAP [38] and silicate-substituted tricalcium 
phosphate (Ca3(PO4)2, TCP) [39]. 
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3.2.1 Silicate-substituted HAP (Si-HAP) 
In Si-HAP, silicate anions (SiO4
4-) substitute phosphate anions (PO4
3-) directly in the apatite 
crystal lattice (Fig. 4, [40, 41]). The amount of silicate is incorporated with only a limited values 
ranging from 0.1 to 1.6 wt% [42]. However, small amounts (0.5 and 1 wt%) are apparently 
sufficient to yield significant improvements in the formation of a new layer of hydroxyapatite 
and in cell proliferation in vitro compared to pure HAP [43]. For example, when pure HAP and 
Si-HAP were immersed in SBF for five weeks, the surface of pure HAP remained almost 
unchanged. In contrast, Si-HAP developed a new surface HAP phase with acicular and plate-like 
morphology, similar to that of new apatite phases grown on bioactive glasses [43]. Additionally, 
in vitro cell culture tests showed that Si-HAP is non-cytotoxic to human osteosarcoma cells 
(HOC) [40]. Cell proliferation was determined by measuring the mitochondrial activity via MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The higher the silicate 
content (up to 1.6 wt%), the higher was the cell proliferation from the first day to one week of 
culture. These findings are also in agreement with the observed effect of zeolites in promoting 
osteoblast proliferation and the expression of transforming growth factor beta (TGF-β) mRNA in 
human osteoblast-like cells [44]. Moreover, in vivo studies indicated that the early bioactivity of 
HAP was significantly improved with the incorporation of silicate ions into the HAP structure. In 
a comparative study, new bone formation was also observed directly on the surfaces and in the 
space between both HAP and Si-HAP (0.8 wt%) granular implants in a white rabbit model [45]. 
The percentage of bone ingrowth for Si-HAP (37.5 ± 5.9 %) was significantly greater than that 
for pure HAP (22.0 ± 6.5 %). Additionally, the percentage of bone/implant coverage was 
significantly greater for Si-HAP (59.8 ± 7.3 %) compared to HAP (47.1 ± 3.6 %) [45]. 
Figure 4 
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Bone remodeling around the implant also occurred faster when silicate was incorporated into 
HAP. This may be due to the higher dissolution rates of the Si-HAP implants compared to pure 
HAP [46]. The substitution of SiO4
4- for PO4
3- in the HAP lattice yields tetrahedral distortion and 
disorder at the hydroxyl site, which could decrease the stability of the apatite structure and also 
decrease the grain size [42]. Compared to pure HAP, the smaller grain size and the formation of 
a less ordered grain boundary in the Si-HAP increases the solubility and affects the timing of 
deposition of the new HAP layer at the bone-implant interface [46-49]. Furthermore, Si has been 
confirmed  by X-ray photoelectron spectroscopy (XPS) to exist as an isolated tetrahedral silicate, 
SiO4
4- group, rather than in a polymeric SiO2 form [50]. The presence of SiO4
4- is important, 
because the SiO4
4- group is preferentially substituted by PO4
3-. The faster in vitro apatite 
formation would be a consequence of this fact. Therefore, the mechanism of the silicate action 
should be considered as a sum of different factors at different levels. 
3.2.2 Silicate-substituted TCP (Si-TCP) 
TCP occurs as alpha (α-TCP) and beta (β-TCP) crystal polymorphs, and the α-TCP phase is 
formed only at temperatures higher than 1,200 ºC. Both phases can be used as orthopaedic 
biomaterials alone or in conjunction with a biodegradable polymer, such as polyglycolic acid 
[51]. Silicate substituted α-TCP (Si-α-TCP) exhibited enhanced bone apposition, bone in-growth 
and cell mediated degradation compared to stoichiometric counterparts [52]. The bioactivity of 
Si-α-TCP increased with an increasing silicate ion substitution [53]. In particular, the surface of 
2.23 wt% Si-α-TCP was partially covered by HAP after one week, and complete coverage was 
attained in the same time on the surface of 8.1 wt% Si-α-TCP. The results were interpreted to 
indicate that porous microstructure of high-concentration Si-TCP helped the dissolution of 
surface ions and the leaching process. Thus, SBF reached super-saturation with respect to HAP 
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in a short time and accelerated the deposition of HAP [53]. In contrast, Camire et al. found the 
thickest HAP layer (the greatest bioactivity) was formed on the surface of 1 wt% Si-TCP, 
compared to 3, 5 wt% Si-TCP [54]. The result was also supported by in vivo study. Comparing 
the cement containing 1% silicate-doped α-TCP with pure α-TCP indicated that silicate presence 
in the matrix enhanced mesenchymal cell differentiation and osteoblast activity in rabbits [54]. In 
another long term in vivo study, the performance of Si-TCP implant was investigated in sheep. 
The authors found that only 10–20% of the scaffold remained after 1 year. The scaffolds were 
completely resorbed after 2 years and were replaced by newly-formed highly-mineralized 
lamellar bone tissue (Fig. 5) [55]. None of the implanted bioceramics were reported to produce 
any adverse effects, such as inflammation. 
Figure 5 
Currently, two different silicate-substituted CaPs are used in clinical bone substitute 
applications. Single-phase Si-HAP materials are manufactured commercially by Apatech Ltd. 
under the trade name ActifuseTM. Si-stabilized CaPs composed primarily of Si-α-TCP are 
manufactured commercially by Millenium Biologix Corporation under the trade name SkeliteTM. 
ActifuseTM and SkeliteTM are both prepared in microporous scaffold and/or granules intended for 
filling bone defects in non-load-bearing applications. 
3.3 Bioactive silicate ceramics 
It was long believed that in order to be bioactive, glasses and glass-ceramics must contain both 
CaO and P2O5, which are the main components of the HAP. However, Ohura et al. [56] observed 
that CaO-SiO2 glasses free of P2O5 as well as those containing very small amounts of P2O5, 
formed a surface HAP layer, when immersed in SBF and interestingly, CaO-P2O5 glasses free of 
SiO2 did not form a HAP layer. This seemed to indicate that bioactive materials can be obtained 
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with compositions based on the CaO-SiO2 system rather than on CaO-P2O5. Taking into account 
these observations, some silicate ceramics such as CaSiO3 have been tested for their potential 
bioactivity. 
3.3.1 CaSiO3 
In the 1990s De Aza and co-workers demonstrated the bioactivity of β-CaSiO3 
(pseudowollastonite, a high temperature polymorph) and α-CaSiO3 (wollastonite, a low 
temperature polymorph). Both CaSiO3 phases can form a surface HAP layer after exposure to 
SBF in vitro and bond to living bone in vivo [57-63]. Subsequently, numerous other studies 
demonstrated that the two CaSiO3 phases are promising candidate materials for bone 
replacement. The two polymorphs of CaSiO3 have identical chemical composition and 
stoichiometry but different crystal structures, which can affect their bioactive properties. In β-
CaSiO3, three silicate tetrahedra are covalently bonded via corner-sharing oxygens to form 
“silicate 3-rings”, whereas α-CaSiO3 is made up of corner-sharing silicate tetrahedral covalently 
linked to form silicate chains (Fig. 6). The silicate “3-rings” structure found in β-CaSiO3 is 
similar to the “3-rings” defect sites in bioactive glasses [64, 65]. The negative charge associated 
with the silicate rings and chains respectively, is electrostatically balanced by Ca2+ ions. The 
high strain associated with the Si-O-Si bond angles in the “3-rings” of β-CaSiO3 makes these 
bonds much more susceptible to hydrolysis than the more stable Si-O-Si bonds in the α-CaSiO3 
chains. This results in the greater solubility and dissolution rate of β-CaSiO3 compared to α-
CaSiO3 [66, 67]. In our group, we studied the kinetics of dissolution of the β-CaSiO3 and α-
CaSiO3 in cell culture medium [68]. Soluble silicate concentrations peaked at higher levels and 
earlier time points for β-CaSiO3 than for α-CaSiO3, consistent with the higher solubility and 
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dissolution rate of the three-ring structure versus the chain silicate structure, which may be the 
reason that β-CaSiO3 is more bioactive than α-CaSiO3. 
Figure 6 
 The cytotoxicity of β-CaSiO3 [69], and the suitability of the material as a substratum for cell 
attachment and its ability to affect osteoblast behavior at a distance from the material surface 
[70] have been evaluated. These experiments demonstrated that β-CaSiO3 were not significantly 
cytotoxic. In our in vitro experiments, we found that a high concentration of silicate (> 120 ppm) 
released from β-CaSiO3 is initially cytotoxic towards human mesenchymal stem cells (hMSCs), 
but cell proliferation increased once lower steady-state soluble silicate concentrations (~ 80 ppm) 
were achieved [67, 68].  
In vivo experiments have also been conducted in which small cylinders of β-CaSiO3 were 
implanted into rat tibias [71]. Histological observations showed the new bone was growing in 
direct contact with the β-CaSiO3 implants after only 3 weeks. After twelve weeks implantation 
the bone in contact with the surface of the β-CaSiO3 appeared to be progressively replaced by 
bone with lamellar structure similar to native bone. At twelve weeks of implantation, new bone 
was still growing at the interface. 
3.3.2 Silicate ceramic composites 
Despite the success of various silicate-based materials for bone replacement, one of the most 
important outstanding problems is implant osteointegration (ingrowth of new bone into the 
implants). When bioactive materials are implanted in vivo, the interactions between the bone 
tissue and these materials usually take place only on their surfaces, while the bulk of the material 
remains unchanged. In multiple cases, this has caused a harmful shear stress at the bone-implant 
interface [71, 72]. To improve the osteointegration, the scaffold must have a high degree of 
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porosity [73]. However, ceramics and bioactive glasses are formed as porous scaffolds, so the 
macroscopic mechanical properties are inadequate for loading-bearing applications because of 
the inherent brittleness of ceramics. This drawback seriously limits the clinical relevance of 
ceramics as synthetic bone scaffolds [29, 74].  
A wide variety of ceramic-ceramic, ceramic-polymer and glass-ceramic composites have been 
developed to address this concern. Bioeutectic® is one such composite, which is capable of 
developing a porous HAP-like structure in situ when they are implanted into a living body. 
Bioeutectic® consists of bioactive β-CaSiO3 and resorbable α-TCP, and presents a high reactivity 
in SBF [63]. When the β-CaSiO3 phase came in contact with the SBF, it reacted via an ion 
exchange of two H+ from the SBF for one Ca2+ from β-CaSiO3 (Fig. 7a). This exchange resulted 
in the formation of a surface amorphous silica layer and also caused the pH at the material/SBF 
interface to increase to 8.9. Immediately following this reaction, the TCP lamellae started to 
react with the Ca2+ and OH- ions present in the confined channels [63]. As a result, a 
pseudomorphic transformation of α-TCP into apatite occurred according to the reaction: 
3Ca3(PO4)2 + Ca
2+ +2OH-      Ca10(PO4)6(OH)2 
The silicate and excess Ca2+, which were not involved in the reaction, migrated through the 
SBF solution away from the interface and into the solution. However, a large increase was not 
detected for Ca2+ concentration in solution. So most of the Ca2+ must have reacted with the 
phosphate of the SBF, leading to the precipitation of HAP on the surface of the material 
according to the reaction: 
6HPO4
2- + 10Ca2+ + 8OH-      Ca10(PO4)6(OH)2 + 6H2O 
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The overall reaction resulted in a large increase in Si concentration in the SBF, a small 
increase in Ca, and a decrease in P, as detected by inductively coupled plasma-atomic emission 
spectroscopy (Fig. 7b). 
Figure 7 
For in vivo studies, Bioeutectic® implants were inserted into the critical size defects of rabbits’ 
tibiae. The results showed a new fully mineralized bone growing in direct contact with the 
implants. The osteoblasts migrated towards the interface and colonized the surface at the contact 
areas with the bone [75]. Thus, Bioeutectic® ceramic could be satisfactorily used for repair or 
replacement of bone. 
3.4 Bioactive porous silica 
In 1992, Li et al. reported the formation of HAP on silica gels when the gels were in contact 
with SBF, but not on dense silica glasses or quartz [76]. The mesoporous silica, having pore 
sizes in the range of 2-90 nm and inner surface silanol, have been shown as bioactive materials 
for tissue regeneration [77]. Bioactivity studies have been carried out on porous silica materials, 
such as SBA-15 (Santa Barbara Amorphous type material), MCM-48 (Mobil Crystalline 
Materials) and MCM-41 [77, 78] (Fig. 8). SBA-15 developed a HAP layer after 30 days 
immersion in SBF, while 60 days were required for MCM-48, a HAP layer did not form at all on 
MCM-41. The different behaviors of the three mesoporous materials were explained on the basis 
of the compositional, textural and structural properties. As already mentioned above, surface 
silanol groups may act as nucleation sites for HAP layer. The silanol group concentration seems 
to be an important factor. The Si-OH concentration per unit surface area was determined by 
thermo-gravimetric analyses (TGA) and N2 adsorption measurements. MCM-41 showed a rather 
low concentration of silanol groups (ca. 2.2 mmol SiOH m-2) compared to SBA-15 (ca. 12.7 
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mmol SiOH m-2) and MCM-48 (ca. 12.9 mmol SiOH m-2). This could be one reason to explain 
the absence of bioactivity in MCM-41. The textural and structural properties of the mesoporous 
silica were also taken into account. Usually, bigger and more accessible pores will favor ion 
diffusion and faster HAP nucleation. SBA-15 showed the largest pore size (8.8 nm) compared 
with MCM-48 (3.6 nm) and MCM-41 (3.6 nm), which may have been responsible for the faster 
HAP nucleation kinetics on SBA-15 compared to MCM-48 and MCM-41. 
Figure 8 
3.5 Bioactive porous silicon 
Microporous Si itself has been shown to be bioactive [79]. Similar to bioactive ceramics, 
hydrated poly-Si layers with suitable microstructure induced HAP deposits. However, the 
semiconductor Si has never been considered a promising biomaterial compared to numerous 
ceramics an  polymers [80] because it has poor hemocompatibility [81]. However,  with simple 
wet-etching (nano-etching) [79] or electrochemical etching techniques in HF-based electrolytes 
[82], Si wafers can be rendered highly bioactive. In vitro studies in SBF showed that 
microporous Si film could induce HAP growth on top of the porous Si and even on neighboring 
areas of bulk Si [79]. Unlike polished Si wafer, which do not degrade in cell medium, porous Si 
could degrade. The experiments showed that freshly etched mesoscale Si (ca. 50 nm, MesPSi) 
degraded faster than macroscale Si (ca. 1 µm, MacPSi) in cell culture medium [82]. 
Furthermore, MacPSi performed better than MesPSi and NanPSi (< 15 nm, nanoscale porous Si) 
in supporting osteoblast growth, differentiation and sustaining their function. In summary, PSi, 
especially MacPSi, which has a large surface-to-volume ratio and flexible surface chemistry, 
make it appealing for microscale devices with both drug-delivery and scaffolding functions. 
These results proved that, if hydrated, Si itself could become an important tissue-compatible 
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biomaterial, and could potentially have widespread applications in biomedicine and tissue 
engineering. However, note that the hydration results in the formation of a surface layer of silica 
or at least silanol surface sites. So the apparent bioactivity of Si is most likely related to silica. 
4. The controversial roles of silicate 
After almost 50 years of development of silicate-based biomaterials as orthopaedic implants, 
the scientific community widely accepts the statements that silicate-substituted materials have 
better biological properties in bone tissue engineering compared to their silicate-free 
counterparts. Based on the reports and discussion above, a passive mechanism has been 
suggested that the presence of Si in the materials cause chemical, physical, or topographical 
changes at the surface that eventually lead to a change of the biological response [83]. 
Yet, the role of silicate may go beyond the simple osteoconductivity (the ability to form HAP 
surface layer that bonds to bone) of silicate materials and may include influences on cell activity 
(cell proliferation and differentiation). The inorganic dissolution products (Si(OH)4, Ca
2+, PO4
3-, 
etc.) released from bioactive glasses have been proven to influence and control the cell cycle of 
osteogenic precursor cells and, ultimately, control cell differentiation [84, 85] at a specific 
concentration range of silicate and Ca2+ [2]. Xynos et al. discovered that critical concentrations 
of these dissolution products could activate or up-regulate seven families of genes in osteogenic 
cells (Table 1). These genes encode transcription of numerous proteins that control the cell cycle, 
proliferation and, ultimately, the differentiation of cells towards the mature osteoblastic 
phenotype [2, 85-87]. Similarly, the dissolution products from Si-TCP were reported to have 
dose-dependent effects on osteoblast proliferation and differentiation, osteoclast formation and 
the resorption process, and also influence the formation of the extracellular matrix [52, 88]. 
Therefore, an “active role” was claimed that silicate can affect bone cell metabolism [5].  
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Table 1 
However, some groups have challenged these concepts. In one study, Si-HAP was 
demonstrated not to dissolve in vitro during more than two weeks in a solution containing 10 
times less Ca2+ and 100 times less phosphate ions than in serum [89]. An in vivo study showed 
material resorption in a weight-bearing long bone sheep model [55], but silicate release 
concentrations or the silicate levels required for therapeutic effects were not determined in any of 
these studies. Therefore, in a critical review [83], it was questioned whether silicate could 
enhance the dissolution of CaP and whether silicate in Si-CaPs can be released in vivo and attain 
a therapeutic level. Furthermore, the roles of silicate to activate or up-regulate genes in cells had 
also been doubted because most of the arguments to support the active roles of silicate were 
based on the dissolution products of bioactive glasses/ceramics, which result in a 
multicomponent solution rather than only dissolved silicate. Moreover, some recent studies 
investigating the essentiality of silicate in growing animals [90-94] have failed to reproduce the 
dramatic results reported by Carlisle [15] and by Schwarz and Milne [18]. Although differences 
in experimental conditions, such as duration of the experiment, age, gender and species of the 
animals, Si source and route of administration, as well as overall nutritional compositions of the 
basal diet may all have contributed to the inter-experimental variance [95], the role of silicate in 
natural bone mineralization might be over-evaluated.  
To address these concerns, Reffitt et al. [96] showed that 10 µM and 20 µM orthosilicic acid 
(H4SiO4) addition to MG63 osteosarcoma cells increased collagen type I (Col I) levels 1.75-fold. 
Increasing concentrations of H4SiO4 (0-50 µM) in primary human osteoblast cells also resulted 
in increased Col I production by increasing mRNA transcription or mRNA stabilization [97, 98], 
which suggested a structural role (stabilization of collagen) or a metabolic role (a co-factor for 
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prolyl hydroxylase) for silicate [95]. H4SiO4 also increased the gene expression of osteocalcin 
and alkaline phosphatase, which are indicators of osteogenic differentiation and mineralization 
[99, 100]. Recently, soluble silicate has been reported to enhance the human osteoblast metabolic 
activity, proliferation, and differentiation [101] and inhibit osteoclast formation and bone 
resorption in vitro [102]. However, none of these studies attempted to determine the mechanistic 
roles of silicate.  
More recently, silica (SiO2) nanoparticles [103] and nanoplatelets [104] were shown to 
mediate potent stimulatory effects on osteoblast differentiation. It was shown that a specific size 
of silica nanoparticle (50 nm in diameter) can antagonize the activation of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB), a signal transduction pathway that can inhibit 
osteoblastic bone formation but promote osteoclastic bone resorption [103]. These silica 
nanoparticles could enter the cells through a caveolae-mediated endocytosis, which triggers the 
stimulation of the mitogen activated protein kinase (MAPK) ERK1/2 (p44/p42) pathway and 
stimulates autophagosome assembly [105]. Although still not completely understood, this 
process (Fig. 9) is stimulatory to osteoblast differentiation and mineralization. However, as the 
authors recognized, subtle changes in charge, shape, size, and/or surface chemistry of these silica 
particles may lead to very different physicochemical responses of cells [103]. For example, 
hexagonal silica nanoparticles with size about 100 nm did not show any bioactive effect in vitro 
[106]. Therefore, it is possible that not silicate but, the nano-sized solid particles could be 
responsible for these positive biological outcomes. Biosilica, the inorganic scaffold that forms 
the siliceous skeleton in sponges, was reported to induce the expression of osteoprotegerin 
(OPG). By using a Boyden chamber co-culture system, some research groups concluded that the 
inhibition of osteoclastogenesis of RAW264.7 pre-osteoclasts was due to the increased level of 
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OPG released by osteoblasts after exposure to silicate. The receptor activator of nuclear factor 
kappa-B ligand (RANKL) may be bound by OPG, which can abolish RANKL function to inhibit 
osteoclast differentiation (Fig. 10, [107]).  
In our group, we have investigated the effects of soluble silicic acid on osteogenic 
differentiation of human mesenchymal stem cells (hMSCs) and osteoclastic differentiation of 
mouse hematopoietic stem cells (mHSCs) [108]. At the physiological pH and concentrations 
below 2 mM, Si exists predominantly as monomeric Si(OH)4. This Si(OH)4 is uncharged at 
neutral pH, but has the tendency to polymerize to polysilicate at Si concentration above ~ 2 - 3 
mM [109]. Below this concentration, our studies showed that soluble Si(OH)4 stimulates the 
proliferation of hMSCs and mHSCs in normal growth medium. More interestingly, we found the 
Si(OH)4 regulated bone formation and bone resorption by promoting osteoblastic gene program 
while repressing osteoclast differentiation [108]. To elucidate the possible molecular 
mechanisms, differential microRNA microarray analyses were applied. Results showed that 
microRNA-146a (miR-146a) was significantly up-regulated in bone cells treated with Si(OH)4. 
Inhibition of miR-146a function by anti-miR-146a suppressed osteogenic differentiation of pre-
osteoblasts, whereas Si(OH)4 treatment counteracted this inhibition and promoted osteoblast-
specific gene transcription and protein expression. Furthermore, both miRNA-146a and Si(OH)4 
were shown to decrease TNFα (or RANKL)-induced activation of NF-κB in bone cells. 
Therefore, our studies established a mechanism for silicate to promote osteogenesis and suppress 
osteoclast formation by antagonizing NF-κB signaling via miR-146a (Figure 11).  
The above discussion suggests an active role for dissolved silicate and silica nanoparticles (50 
nm size) in affecting cell behavior in vitro by specific molecular biology pathways These 
ground-breaking studies are showing that silicate not only promotes osteogenic differentiation of 
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hMSCs but also suppresses osteoclastic differentiation of mHSCs and osteoclast bone resorption 
activity [102-105]. Thus, silicate-based biomaterials that release soluble silicate can be 
considered not simply as bone graft substitutes but are, effectively, drug delivery systems in 
which soluble silicate acts like a drug. For example, Si(OH)4 could be used as a nutritional 
supplement to treat osteoporosis, a disease which results due to an imbalance between bone 
formation and resorption, which is common in women after menopause and older men [21, 95].  
Figure 9 
Figure 10 
Figure 11 
5. Summary 
The effect of silicate on bone formation has long been recognized and debated in the literature. 
Controversy arose in resolving whether an effect exists and, if so, is it by a passive or active 
mechanism because of differences in experimental conditions, cell types and animal models, 
presence of other dissolved ions along with silicate, the effects of truly dissolved silicate versus 
the effect of solid biomaterial surfaces, dose-effects of dissolved silicate released from various 
silica-containing biomateirals etc. The results of more carefully-designed recent studies are 
adding to a growing body of evidence for an active role of dissolved silicate and solid silica 
nanoparticles of specific size.  
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FIGURE CAPTIONS  
Figure 1. Beneficial effect of silicate on bone is illustrated by these four-week old chickens. The 
chicken to the left was fed a diet with high levels of silicate (100 mg/g) while the one to the right 
was fed a diet with low levels of silicate (2 mg/g). (Photo: Carlisle, 1972) 
Figure 2. Bioactive regions in the CaO-SiO2-Na2O system. All glasses contain 6% wt of P2O5. 
Glasses and glass-ceramics that have a composition falling inside region A develop HAP both in 
vitro and in vivo. Compositions inside the dashed line also bond to soft tissues. The compositions 
in region B such as window and bottle glass are inert and a fibrous capsule is formed around 
them when implanted; those in region C are completely dissolved at 10-30 days following 
implantation. Region D is a non-glass forming and non-bonding region. Glasses within region E 
(dashed curves) adhere to collagen, the soft tissue component of bone. Reproduced with 
permission [29]. Copyright 2005, John Wiley & Sons, Inc. 
Figure 3. Schematic illustration of the reaction sequence leading to HCA formation according to 
Hench and co-workers, from a bioactive melt-prepared CaO-SiO2 glass. Reproduced with 
permission [37]. Copyright 2012, The Royal Society. 
Figure 4. Schematic diagram of the lattices of pure HA and Si-HA. Silicate anions (SiO4
4-) 
substitute phosphate anion (PO4
3-) in the apatite crystal lattice albeit to a limited extent. 
Reproduced with permission [41]. Copyright 2012, IOP Publishing Ltd. 
Figure 5. Gross cross section (top panels) and contact microradiographs (bottom panels) of Si-α- 
TCP scaffolds implanted in the tibiae of sheep sacrificed at 3, 6 and 24 months after surgery. At 
3 months, the cross-sectional shape of the implant is still recognizable and the newly-formed 
bone is mainly deposited on its external surface. At 6 months, the loss of the central canal of the 
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hollow implant occurs as a result of both implant fragmentation and new bone formation within 
the inner pores. At 24 months, the implant phase is markedly reduced, and very few and sparse 
fragments can be detected (arrows). Scale bar shows 5 mm. Reproduced with permission [55]. 
Copyright 2006, Mary Ann Liebert, Inc. 
Figure 6. S hematic of the crystal structure of β-CaSiO3 and α-CaSiO3. Legend for atoms in 
panels: O = red, Si = blue, Ca = green. 
Figure 7. Schematic representation of the first stages (a) and final stage (b) of HAP formation in 
eutectic material after immersion in SBF. Reproduced with permission [63] with slight 
modification. Copyright 1997, published by Elsevier Ltd. 
Figure 8. SEM micrographs and EDS spectra of SBA-15, MCM-48 and MCM-41 materials at 0, 
15, 30 and 60 d. Reproduced with permission [77]. Copyright 2006, The Royal Society. 
Figure 9. Schematic representing the intrinsic biological effects of silica-based nanoparticles on 
osteoblast differentiation. Nanoparticles are internalized by caveolae-mediated endocytosis, 
which triggers a signal transduction pathway dependent on ERK1/2. This stimulation of ERK1/2 
is necessary for the processing of LC3β form I to the activated form II. Nanoparticles are bound 
by both LC3 and p62, resulting in the formation of autophagosomes. The stimulation of 
autophagy is necessary for osteoblast differentiation and mineralization. Reproduced with 
permission [105]. Copyright 2014, published by American Chemical Society. 
Figure 10. Proposed effects of biosilica on osteoblasts, osteoclasts, and their progenitors. 
Biosilica enhances expression of OPG in osteoblasts. Osteoblasts have the potential to 
differentiate to osteocytes and lining cells. OPG counteracts various effects of RANKL, a 
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cytokine that induces pre-osteoclast maturation and osteoclast activation. Reproduced with 
permission [106]. Copyright 2014, published by Elsevier Ltd. 
Figure 11. Si(OH)4-mediated regulation of NF-κB via miR-146a in bone cells. Si(OH)4 may 
enter the cell through Na+-HCO3
- co-transporter (NBC-1). Within the cell Si(OH)4 can induce 
the expression of endogenous miR-146a to reduce activation of NF-κB. The inhibition of NF-κB 
results in activation of Runx2, the master transcription factor necessary for osteoblast precursor 
differentiation. This deactivation of NF-κB also inhibits the expression of NFATc1, the key 
transcription gene for osteoclast precursor differentiation. Thus, Si(OH)4 can stimulate osteoblast 
differentiation and inhibit osteoclast differentiation by antagonizing NF-κB activation via miR-
146a, which implies a potential role in bone remodeling. Reproduced with permission [108]. 
Copyright 2016, published by Elsevier Ltd. 
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Table 1. Families of genes in primary human osteoblasts activated or up-regulated by ionic 
dissolution products of bioactive glasses. Reproduced with permission [2]. Copyright 2008 
published by Elsevier Ltd. 
 
 
 
Transcription factors and cell cycle regulators Activation (%) 
RCL growth-related c-myc-responsive gene 500 
G1/S-specific cyclin D1 (CCND1) 400 
26S proteinase regulatory subunit 6A 400 
Cyclin-dependent kinase inhibitor 1 (CDKN1A) 350 
cAMP-dependent transcription factor ATF-4 240 
Cyclin K 200 
DNA synthesis, repair and recombination Up-regulation (%) 
DNA exclusion repair protein ERCC 300 
mutL protein homolog 300 
High-mobility-group protein (HMG-1) 230 
Replication factor C 38 kDa subunit (RFC38) 200 
Apoptosis regulators Up-regulation (%) 
Defender against cell death 1 (DAD-1) 450 
Ca-dependent proteinase small (regulatory) subunit; calpain 410 
Deoxyribonuclease II (Dnase II) 160 
Growth factors and cytokines Activation (%) 
Insulin-like growth factor II (IGF-II) 300 
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Macrophage-specific colony stimulating factor (CSF1;  
260 
MCSF)  
Bone-derived growth factor 200 
Vascular endothelial growth factor precursor (VEGF) 200 
Cell surface antigens and receptors Activation (%) 
CD44 antigen hematopoetic form precursor 700 
Fibronectin receptor beta subunit; integrin beta 1 600 
N-sam; fibroblast growth factor receptor-1 precursor 300 
Vascular cell adhesion protein-1 precursor (V-CAM1) 200 
Signal transduction molecules Activation (%) 
MAP kinase-activated protein kinase 2 (MAPKAP kinase 2) 600 
Dual specificity nitrogen-activated protein kinase 2 200 
ADP-ribosylation factor 1 200 
Extracellular matrix compounds Activation (%) 
Matrix metalloproteinase 14 precursor (MMP 14) 370 
Matrix metalloproteinase 2 (MMP 2) 270 
Metalloproteinase 1 inhibitor precursor (TIMP 1) 220 
TIMP 2 (MI) 220 
Bone proteoglycan II precursor; decorin 200 
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Figure 1. Beneficial effect of silicate on bone is illustrated by these four-week old chickens. The chicken to 
the left was fed a diet with high levels of silicate (100 mg/g) while the one to the right was fed a diet with 
low levels of silicate (2 mg/g). (Photo: Carlisle, 1972)  
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Figure 2. Bioactive regions in the CaO-SiO2-Na2O system. All glasses contain 6% wt of P2O5. Glasses and 
glass-ceramics that have a composition falling inside region A develop HAP both in vitro and in vivo. 
Compositions inside the dashed line also bond to soft tissues. The compositions in region B such as window 
and bottle glass are inert and a fibrous capsule is formed around them when implanted; those in region C 
are completely dissolved at 10-30 days following implantation. Region D is a non-glass forming and non-
bonding region. Glasses within region E (dashed curves) adhere to collagen, the soft tissue component of 
bone. Reproduced with permission [29]. Copyright 2005, John Wiley & Sons, Inc.  
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Figure 3. Schematic illustration of the reaction sequence leading to HCA formation according to Hench and 
co-workers, from a bioactive melt-prepared CaO-SiO2 glass. Reproduced with permission [37]. Copyright 
2012, The Royal Society.  
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Figure 4. Schematic diagram of the lattices of pure HA and Si-HA. Silicate anions (SiO44-) substitute 
phosphate anion (PO43-) in the apatite crystal lattice albeit to a limited extent. Reproduced with permission 
[41]. Copyright 2012, IOP Publishing Ltd.  
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Figure 5. Gross cross section (top panels) and contact microradiographs (bottom panels) of Si-α- TCP 
scaffolds implanted in the tibiae of sheep sacrificed at 3, 6 and 24 months after surgery. At 3 months, the 
cross-sectional shape of the implant is still recognizable and the newly-formed bone is mainly deposited on 
its external surface. At 6 months, the loss of the central canal of the hollow implant occurs as a result of 
both implant fragmentation and new bone formation within the inner pores. At 24 months, the implant 
phase is markedly reduced, and very few and sparse fragments can be detected (arrows). Scale bar shows 5 
mm. Reproduced with permission [55]. Copyright 2006, Mary Ann Liebert, Inc.  
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Figure 6. Schematic of the crystal structure of β-CaSiO3 and α-CaSiO3. Legend for atoms in panels: O = 
red, Si = blue, Ca = green.  
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Figure 7. Schematic representation of the first stages (a) and final stage (b) of HAP formation in eutectic 
material after immersion in SBF. Reproduced with permission [63] with slight modification. Copyright 1997, 
published by Elsevier Ltd.  
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Figure 8. SEM micrographs and EDS spectra of SBA-15, MCM-48 and MCM-41 materials at 0, 15, 30 and 60 
d. Reproduced with permission [77]. Copyright 2006, The Royal Society.  
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Figure 9. Schematic representing the intrinsic biological effects of silica-based nanoparticles on osteoblast 
differentiation. Nanoparticles are internalized by caveolae-mediated endocytosis, which triggers a signal 
transduction pathway dependent on ERK1/2. This stimulation of ERK1/2 is necessary for the processing of 
LC3β form I to the activated form II. Nanoparticles are bound by both LC3 and p62, resulting in the 
formation of autophagosomes. The stimulation of autophagy is necessary for osteoblast differentiation and 
mineralization. Reproduced with permission [105]. Copyright 2014, published by American Chemical 
Society.  
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Figure 10. Proposed effects of biosilica on osteoblasts, osteoclasts, and their progenitors. Biosilica enhances 
expression of OPG in osteoblasts. Osteoblasts have the potential to differentiate to osteocytes and lining 
cells. OPG counteracts various effects of RANKL, a cytokine that induces pre-osteoclast maturation and 
osteoclast activation. Reproduced with permission [106]. Copyright 2014, published by Elsevier Ltd.  
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Figure 11. Si(OH)4-mediated regulation of NF-κB via miR-146a in bone cells. Si(OH)4 may enter the cell 
through Na+-HCO3- co-transporter (NBC-1). Within the cell Si(OH)4 can induce the expression of 
endogenous miR-146a to reduce activation of NF-κB. The inhibition of NF-κB results in activation of Runx2, 
the master transcription factor necessary for osteoblast precursor differentiation. This deactivation of NF-κB 
also inhibits the expression of NFATc1, the key transcription gene for osteoclast precursor differentiation. 
Thus, Si(OH)4 can stimulate osteoblast differentiation and inhibit osteoclast differentiation by antagonizing 
NF-κB activation via miR-146a, which implies a potential role in bone remodeling. Reproduced with 
permission [108]. Copyright 2016, published by Elsevier Ltd.  
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